1[1]Anzueto A.Clinical course of chronic obstructive pulmonary disease:review of therapeutic interventions[J].Am J Med,2006,119(10):46-53.
2[2]Anthonisen NR,Skeans MA,Wise RA,et al.The effects of a smoking cessation intervention on 14.5-year mortality:a randomized clinical trial[J].Ann Intern Med,2005,142(4):233-239.
3[3]Campos MA,Wanner A.The rationale for pharmacologic therapy in stable chronic obstructive pulmonary disease[J].Am J Med Sci,2005,329(4):181-189.
4[4]Bonay M,Bancal C,Crestani B.Benefits and risks of inhaled corticosteroids in chronic obstructive pulmonary disease[J].Drug Saf,2002,25(1):57-71.
5[5]MacIntyre NR.Corticosteroid therapy and chronic obstructive pulmonary disease[J].Respir Care,2006,51(3):289-96.
6Lundblad L K,Thompson Figueroa J,Leclair T,et al.Tumor necrosis factor-alpha over-expression in lung disease:a single cause behind a complex phenotype[J].Am J Respir Crit Care Med,2005,171(12):1363-1370.
7Rabinowitz M H,Andrews R C,Becherer J D,et al.Design of selective and soluble inhibitors of tumor necrosis factor-alpha converting enzyme (TACE)[J].J Med Chem,2001,44(24):4252-4267.
8van Driel M F.Phosphodiesterase inhibitors:effectiveness and new applications[J].Ned Tijdschr Geneeskd,2006,150(29):1613-1616.
9Currie G P,Butler C A,Anderson W J,et al.Phosphodiesterase-4 inhibitors in chronic obstructive pulmonary disease:a new approach to oral treatment[J].Br J Clin Pharmacol,2008,65(6):803-810.
10Rahman I.Antioxidant therapeutic advances in COPD[J].Ther Adv Respir Dis,2008,2(6):351-374.
